Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001493152-25-019697
Filing Date
2025-10-27
Accepted
2025-10-27 13:26:15
Documents
17
Period of Report
2025-10-27

Document Format Files

Seq Description Document Type Size
1 DEF 14A formdef14a.htm   iXBRL DEF 14A 968706
2 GRAPHIC formdef14a_001.jpg GRAPHIC 344694
3 GRAPHIC formdef14a_002.jpg GRAPHIC 237364
  Complete submission text file 0001493152-25-019697.txt   3209334

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE lixt-20241231.xsd EX-101.SCH 6111
5 XBRL DEFINITION FILE lixt-20241231_def.xml EX-101.DEF 11006
6 XBRL LABEL FILE lixt-20241231_lab.xml EX-101.LAB 61993
7 XBRL PRESENTATION FILE lixt-20241231_pre.xml EX-101.PRE 46078
19 EXTRACTED XBRL INSTANCE DOCUMENT formdef14a_htm.xml XML 163152
Mailing Address 433 PLAZA REAL SUITE 275 BOCA RATON FL 33432
Business Address 433 PLAZA REAL SUITE 275 BOCA RATON FL 33432 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39717 | Film No.: 251418888
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)